Her2-positive Lung Cancer Treated With Dedicated Drug

clinical trial

Details

Instance of: clinical trial
Start time: May 2019
End time: December 2020
Country: France
Main subject: ERBB2, lung cancer
clinical trial phase: phase II clinical trial
minimum age: 18
number of participants: 45
research intervention: pertuzumab
research site: Centre Hospitalier Universitaire Toulouse, Institut Gustave Roussy
short name: R2D2
sponsor: French Cooperative Thoracic Group
study type: interventional study
title: Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving Docetaxel

Nothing in the MetaHistoryBook collection references this item yet.